NovelStem International (NovelStem International) 5-Year EBITDA Growth Rate : 40.30% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is NovelStem International 5-Year EBITDA Growth Rate?

NovelStem International's EBITDA per Share for the three months ended in Dec. 2023 was $0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 30.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 40.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 20.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of NovelStem International was 66.10% per year. The lowest was -51.60% per year. And the median was 7.70% per year.

Competitive Comparison of NovelStem International's 5-Year EBITDA Growth Rate

For the Diagnostics & Research subindustry, NovelStem International's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovelStem International's 5-Year EBITDA Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NovelStem International's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where NovelStem International's 5-Year EBITDA Growth Rate falls into.

NovelStem International 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

NovelStem International (OTCPK:NSTM) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

NovelStem International 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of NovelStem International's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

NovelStem International (NovelStem International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NovelStem International Corp (OTCPK:NSTM) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

2255 Glades Road, Suite 221A, Boca Raton, FL, USA, 33431

Website

https://www.novelstem.com

NovelStem International Corp owns novel stem-cell-based diagnostic technology for predicting patients' resistance to cancer therapies. The technology is also being used for genetic research related to other medical therapies.

Executives

Baker Street Capital Management, Llc	10 percent owner	1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Vadim Perelman	10 percent owner	1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Baker Street Capital L.p.	10 percent owner	1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Stephen Gans	director, 10 percent owner	14850 NW 44TH COURT, OPA LOCKA FL 33054
Shannon River Partners Lp	10 percent owner	850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Shannon River Fund Management Co Llc	10 percent owner	850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Shannon River Partners Ii, Lp	10 percent owner	850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Doonbeg Fund Lp	10 percent owner	850 THIRD AVE, 13TH FLOOR, New York ny 10022
Spencer M. Waxman	director	C/O SHANNON RIVER PARTNERS, 800 THIRD AVENUE 30TH FLOOR, NEW YORK NY 10022
Stanley Morgan	10 percent owner	1585 BROADWAY, NEW YORK NY 10036
Robert D. Epstein	director	2255 GLADES ROAD, BOCA RATON FL 33431
Coghill Capital Management Llc	10 percent owner	233 SOUTH WACKER DRIVE, SUITE 8439, CHICAGO IL 60606
Ccm Master Fund Ltd	10 percent owner	C/O MORGAN STANLEY FUND SERVICES (CAYMAN, LTD CENTURY YARD CRICKET SQ HUTCHINGS DR, PO BOX 2681 GEORGE TOWN E9 00000
Clint D Coghill	10 percent owner
Scott Gomez	officer: Chief Accounting Officer

NovelStem International (NovelStem International) Headlines

From GuruFocus

NewStem Announces $4 million Seed Investment

By PRNewswire PRNewswire • 07-16-2018

Hollywood Media Corp. Reports Operating Results (10-K/A)

By gurufocus 10qk • 04-30-2010

Hollywood Media Corp. Reports Operating Results (10-Q)

By gurufocus • 05-11-2009

Hollywood Media Corp. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-17-2010